| Identification | Back Directory | [Name]
2-(3,4-dimethoxyphenyl)-4-(4-methylphenyl)-2,3-dihydro-1,5-benzothiazepine | [CAS]
321686-01-5 | [Synonyms]
α-Glucosidase-IN-21
2-(3,4-dimethoxyphenyl)-4-(4-methylphenyl)-2,3-dihydro-1,5-benzothiazepine | [Molecular Formula]
C24H23NO2S | [MOL File]
321686-01-5.mol | [Molecular Weight]
389.51 |
| Hazard Information | Back Directory | [Uses]
α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity[1]. | [in vivo]
α-Glucosidase-IN-21 (Compound 2B; 10 and 20 mg/kg; p.o.; daily, for 4 weeks) has anti-diabetic activity in Streptozocin (HY-13753)-induced diabetic rats[1].
α-Glucosidase-IN-21 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats[1].
α-Glucosidase-IN-21 (2000 mg/kg; p.o.; daily, for 2 weeks) demonstrates no mortality in mice[1]. | Animal Model: | Male Wistar albino rats (170-200 g), Streptozotocin-induced diabetes model[1] | | Dosage: | 10 and 20 mg/kg | | Administration: | Oral administration; daily, for 4 weeks | | Result: | Decreased the level of blood glucose, reversed Streptozocin-induced body weight loss. Showed antihyperlipidemic effects on Streptozotocin-induced diabetes, reduced to a significant level of serum biomarkers. |
| [References]
[1] Mehmood R, et al. Synthesis of Novel 2, 3-Dihydro-1, 5-Benzothiazepines as α-Glucosidase Inhibitors: In Vitro, In Vivo, Kinetic, SAR, Molecular Docking, and QSAR Studies. ACS Omega, 2022 Aug 17. |
|
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
|